Cancer Dx Panel expansion and inVue Dx FNA cytology rollout advance veterinary cancer care, enabling comprehensive mast cell tumor testing for dogs.
IDEXX Laboratories Inc. (Nasdaq: IDXX) has developed a diagnostic test to help veterinarians detect kidney injury in cats and dogs at an earlier stage to improve treatment. The Westbrook-based ...
The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 ...
The Catalyst Cortisol Test will be available in the U.S. and Canada at the end of July 2025, with a global rollout to the installed base of more than 75,000 Catalyst chemistry analyzers expected to ...
Hosted on MSN
IDEXX Laboratories Shares Surge 7% After Beating Q3 Estimates on Strong Diagnostic Demand
IDEXX Laboratories (NASDAQ:IDXX) shares jumped 7.2% on Monday after the animal health diagnostics leader reported third-quarter earnings and revenue that topped Wall Street expectations, supported by ...
IDEXX Labs offers veterinary diagnostic instruments, rapid assay test kits, reference lab services, water quality testing products, and veterinary practice management software. The company generates ...
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced two major advancements in veterinary cancer diagnostics: the expansion of its IDEXX Cancer Dx™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results